(1 - 31 von 43
)
FDA approves Samsung/Merck & Co's Herceptin biosimilarPharmaphorum
pharmaphorum.com
AP — Sang-Jin Pak, senior vice president and head of commercial division, Samsung Bioepis, said: “For many cancer patients in the US, battling AP — Sang-Jin Pak, senior vice president and head of commercial division, Samsung Bioepis, said: “For many cancer patients in the US, battling ...
News ReleasesSAMSUNG BIOEPIS
m.samsungbioepis.com
AP — ” said Sang-Jin Pak, Executive Vice President and Head of Commercial Division, at Samsung Bioepis. SB17, a proposed biosimilar to Stelara AP — ” said Sang-Jin Pak, Executive Vice President and Head of Commercial Division, at Samsung Bioepis. SB17, a proposed biosimilar to Stelara ...
Samsung Bioepis Hunts for More Deals Like Takeda ...Bloomberg Law News
news.bloomberglaw.com
AP — “Biosimilars will remain our backbone,” Chief Operating Officer Sang-Jin Pak said in an interview Wednesday after Samsung Bioepis and partner AP — “Biosimilars will remain our backbone,” Chief Operating Officer Sang-Jin Pak said in an interview Wednesday after Samsung Bioepis and partner ...
Samsung Bioepis and Sandoz Partner to Launch SB 히트뉴스
www.hitnews.co.kr
AP — Sang-Jin Pak, Executive Vice President and Head of the Commercial Division, remarked, "This partnership underscores our unwavering AP — Sang-Jin Pak, Executive Vice President and Head of the Commercial Division, remarked, "This partnership underscores our unwavering ...
sortiert nach Relevanz / Datum